Goldman Sachs Group Inc Vertex Pharmaceuticals Inc Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,358,534 shares of VRTX stock, worth $613 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

1,358,534

Previous 2,062,499 34.13%

Holding current value

$613 Million

Previous $967 Million 34.64%

% of portfolio

0.1%

Previous 0.17%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$460.0 - $505.78 $324 Million - $356 Million	-703,965 Reduced 34.13%	1,358,534 $632 Million
Q2 2024 Aug 13, 2024	BUY	$392.81 - $485.53 $260 Million - $321 Million	661,539 Added 47.22%	2,062,499 $967 Million
Q1 2024 May 15, 2024	SELL	$407.69 - $446.08 $34.2 Million - $37.5 Million	-83,974 Reduced 5.66%	1,400,960 $586 Million
Q4 2023 Feb 13, 2024	SELL	$343.0 - $410.68 $72.2 Million - $86.4 Million	-210,391 Reduced 12.41%	1,484,934 $604 Million
Q3 2023 May 14, 2024	BUY	$338.18 - $362.46 $71.2 Million - $76.3 Million	210,391 Added 14.17%	1,695,325 $590 Million
Q3 2023 Nov 14, 2023	SELL	$338.18 - $362.46 $40.8 Million - $43.7 Million	-120,547 Reduced 6.64%	1,695,325 $590 Million
Q2 2023 May 14, 2024	BUY	$314.42 - $351.91 $32.7 Million - $36.6 Million	104,141 Added 6.08%	1,815,872 $639 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $32.7 Million - $36.6 Million	104,141 Added 6.08%	1,815,872 $639 Million
Q1 2023 May 14, 2024	BUY	$283.23 - $323.1 $11.1 Million - $12.7 Million	39,358 Added 2.35%	1,711,731 $539 Million
Q1 2023 May 11, 2023	BUY	$283.23 - $323.1 $11.1 Million - $12.7 Million	39,358 Added 2.35%	1,711,731 $539 Million
Q4 2022 May 14, 2024	SELL	$285.76 - $321.48 $13.8 Million - $15.6 Million	-48,374 Reduced 2.81%	1,672,373 $483 Million
Q4 2022 Feb 13, 2023	SELL	$285.76 - $321.48 $13.8 Million - $15.6 Million	-48,374 Reduced 2.81%	1,672,373 $483 Million
Q3 2022 May 14, 2024	BUY	$273.83 - $305.53 $184 Million - $206 Million	673,107 Added 64.25%	1,720,747 $498 Million
Q3 2022 Nov 10, 2022	BUY	$273.83 - $305.53 $184 Million - $206 Million	673,107 Added 64.25%	1,720,747 $498 Million
Q2 2022 May 14, 2024	SELL	$234.96 - $292.55 $103 Million - $128 Million	-437,294 Reduced 29.45%	1,047,640 $295 Million
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $46.1 Million - $57.4 Million	-196,067 Reduced 15.76%	1,047,640 $295 Million
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $12.5 Million - $14.7 Million	56,330 Added 4.74%	1,243,707 $325 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $36.5 Million - $46.1 Million	-206,385 Reduced 14.81%	1,187,377 $261 Million
Q3 2021 Nov 10, 2021	BUY	$181.39 - $202.99 $253 Million - $283 Million	1,393,762 New	1,393,762 $253 Million

Others Institutions Holding VRTX

# of Institutions

1,721

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Vertex Pharmaceuticals Inc Transaction History